cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Affimed Nv
14 own
21 watching
Current Price
$0.83
$-0.05
(-5.23%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
123.61M
52-Week High
52-Week High
3.4
52-Week Low
52-Week Low
0.5502
Average Volume
Average Volume
1.32M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization123.61M
icon52-Week High3.4
icon52-Week Low0.5502
iconAverage Volume1.32M
iconDividend Yield--
iconP/E Ratio--
What does the Affimed Nv do?
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Read More
News & Events about Affimed Nv.
Globe Newswire
1month ago
AFM24-101 phase 1/2 interim results from the non-small cell lung cancer cohort accepted for poster presentationAFM24-101 phase1/2 interim results from the colorectal cancer cohort accepted for online publication HEIDELBERG, Germany, April 26, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a ...
Globe Newswire
5 months ago
AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM)Initiation of AFM28 clinical development in the first half of 2023 on track HEIDELBERG, Germany, Dec. 22, 2022 (...
Globe Newswire
5 months ago
AFM28 efficiently directs allogeneic NK cells to CD123-positive leukemic cells, including leukemic stem and progenitor cells, inducing their depletion in samples of patients with Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)Leukemia cell lysis was independent of differences in ...
Globe Newswire
6 months ago
Comprehensive correlative science findings from patients treated with AFM24 monotherapy indicate an activation of NK cells and their migration to the tumorInitial signs of clinical activity and a well-managed safety profile with no dose-limiting toxicities were shown in preliminary data from the ...
Globe Newswire
6 months ago
Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patientsAffimeds AFM13 in combination with cord blood-derived NK cells demonstrated exceptionally high response rates in relapsed and refractory CD30-positive lymphoma patientsAB-101 is ...
Frequently Asked Questions
Frequently Asked Questions
What is Affimed Nv share price today?
plus_minus_icon
Can Indians buy Affimed Nv shares?
plus_minus_icon
How can I buy Affimed Nv shares from India?
plus_minus_icon
Can Fractional shares of Affimed Nv be purchased?
plus_minus_icon
What are the documents required to start investing in Affimed Nv stocks?
plus_minus_icon
What is today’s traded volume of Affimed Nv?
plus_minus_icon
What is today’s market capitalisation of Affimed Nv?
plus_minus_icon
What is the 52-Week High and Low Range of Affimed Nv?
plus_minus_icon
What percentage is Affimed Nv down from its 52-Week High?
plus_minus_icon
What percentage is Affimed Nv up from its 52-Week Low?
plus_minus_icon
Current Price
$0.83
$-0.05
(-5.23%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$1.72
$0.05 (2.69 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.50
$0.00 (0.00 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$7.06
$0.03 (0.43 %)
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
$1.58
$-0.04 (-2.47 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$1.72
$0.05 (2.69 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.50
$0.00 (0.00 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$7.06
$0.03 (0.43 %)
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
$1.58
$-0.04 (-2.47 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00